Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Simcere Pharmaceutical Group Limited
先聲藥業集團有限公司
(Incorporated in Hong Kong with limited liability)
(Stock code: 2096)

CHANGE OF JOINT COMPANY SECRETARY AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

CHANGE OF JOINT COMPANY SECRETARY

The board (the "**Board**") of directors (the "**Directors**") of Simcere Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") hereby announces that Mr. WAN Yushan (萬玉山) ("**Mr. WAN**") has ceased to act as a joint company secretary of the Company (the "**Joint Company Secretary**") with effect from August 20, 2026. Mr. WAN will remain as an executive Director and the chief financial officer of the Company.

Mr. WAN confirmed that he has no disagreement with the Board and that there is no matter in relation to his resignation as a Joint Company Secretary that needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

The Board further announces that Mr. ZHU Da (朱達) ("**Mr. ZHU**"), currently the secretary to the Board of the Company, has been concurrently appointed as a Joint Company Secretary to replace Mr. WAN with effect from August 20, 2026. Ms. MAK Po Man Cherie (麥寶文) ("**Ms. MAK**"), who meets the requirements under Rule 3.28 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), currently the other Joint Company Secretary, will continue to act as a Joint Company Secretary and perform and discharge the duties of a company secretary under the Listing Rules.

The biographical details of each of Mr. ZHU and Ms. MAK are set out below:

Mr. ZHU, aged 34, was appointed as the secretary to the Board of the Company on August 21, 2024. He is primarily responsible for overseeing the corporate governance, capital-markets affairs and investor relations, while advising the board and senior management on key governance and disclosure matters. Mr. ZHU has over twelve years of experience in the field of investment banking and corporate management. Prior to joining the Group, Mr. Zhu served successively as senior associate, vice president and senior vice president in the investment banking department of Morgan Stanley Asia Limited from November 2018 to July 2024, and served as an analyst and associate of the investment banking department of China International Capital Corporation Limited (中國國際金融股份有限公司) from June 2014 to August 2018. Mr. ZHU obtained a bachelor's degree in economics from Indiana University-Bloomington of the United States in May 2014.

Ms. MAK was appointed as a Joint Company Secretary on March 25, 2026. Ms. MAK is the Vice President of SWCS Corporate Services Group (Hong Kong) Limited. She has worked for various professional firms and listed companies in Hong Kong, with over 20 years of experience in the fields of audit, accounting, corporate finance, compliance and corporate secretarial matters. Ms. MAK obtained a Master of Corporate Governance degree from The Hong Kong Polytechnic University in 2017. She was admitted as an associate member of The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in 2017, a member of the Hong Kong Institute of Certified Public Accountants in 2003, and a fellow member of the Association of Chartered Certified Accountants in 2006.

WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

Having considered Mr. ZHU's background and experience, the Board is of the view that Mr. ZHU is able to properly discharge his functions as a Joint Company Secretary notwithstanding the fact that Mr. ZHU does not possess the qualifications of a company secretary as required under Rule 3.28 of the Listing Rules. The Company has applied for and the Stock Exchange has granted the Company a waiver from strict compliance with Rules 3.28 and Rule 8.17 of the Listing Rules (the "**Waiver**") for a period of three years commencing from August 20, 2026 (the "**Waiver Period**").

The grounds for seeking of the Waiver are (i) Mr. ZHU joined the Group in August 2024, and currently serves as the secretary to the Board of the Company, primarily responsible for overseeing the corporate governance, capital-markets affairs and investor relations, while advising the board and senior management on key governance and disclosure matters. He has accumulated abundant knowledge about the business operations and corporate governance of the Group with a strong recognition of the corporate culture of the Group. By virtual of his position within the Group, Mr. ZHU has worked closely with the Directors and the management of the Company, which enables him to perform the duties of a company secretary in the most effective and efficient manner; (ii) Mr. ZHU has attended trainings on, among other things, laws and regulations and the Listing Rules. By attending these trainings, Mr. ZHU is familiar with the Listing Rules, and other relevant Hong Kong laws and regulations including but not limited to the Securities and Futures Ordinance, Companies Ordinance and the Takeovers Code, and can discharge the functions as a Joint Company Secretary; and (iii) Ms. MAK, who satisfies the requirements under Rule 3.28 of the Listing Rules, will continue to serve as a Joint Company Secretary. Ms. MAK has over 20 years of experience in the fields of audit, accounting, corporate finance, compliance and corporate secretarial matters, thus can leverage her expertise to assist Mr. ZHU to better discharge his responsibilities as a Joint Company Secretary.

The Waiver is granted on the conditions that, (i) Mr. ZHU must be assisted by Ms. MAK during the Waiver Period; and (ii) the Waiver could be revoked if there is any material breach of the Listing Rules by the Company.

Before the end of the Waiver Period, the Company must demonstrate and seek confirmation from the Stock Exchange that Mr. ZHU, having had the benefit of Ms. MAK's assistance during the Waiver Period, has attained the relevant experience and is capable of discharging the functions of company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary.

The Stock Exchange may change or withdraw the Waiver if the Company's situation changes.

By order of the Board
Simcere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer

Hong Kong, August 20, 2026

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director; Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; Mr. TANG Renhong as the non-executive Director; Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.